Speaker Story

Savan is the Founder and CEO of BioTrillion, a health technology company developing an AI-based platform called BioEngine4D to generate novel “digital biomarkers” in Neurology with applications in: data-driven drug development and digitally detecting developing diseases.
Previously, Savan spent the majority of his 15 year career in the Life Sciences industry working with hundreds of public and private corporations as a Healthcare Investment Banker at Citigroup, Deutsche Bank.  From Analyst through Managing Director, he led ~40 M&A, IPO, and financing deals, totaling $35+ billion in value, and experienced many invaluable business and scientific lessons from his work with clients across the spectrum of drug, diagnostic, and device technologies.  Some of these companies included Amgen, Anacor, Boston Scientific, Eli Lilly, Intermune, Map Pharma, Masimo, Medtronic, Omeros, Pacific Biosciences, and many others.  While a Vice President at Deutsche Bank, Savan was selected to lead the firm's build-out of its Healthcare business into Asia, leading to IPO's of the two largest healthcare companies in China: Shanghai Pharma and Fosun Pharma.  Savan began his career as a Bioengineer at Life Technologies.
Savan graduated with a M.S.E. in Bioengineering from the University of Pennsylvania and a B.S.E. in Bioengineering focused in Computer Science from the University of California at Berkeley.
After many years of academic and professional experience in the healthcare field, a deeply personal experience later in life gave Savan a new perspective into how much healthcare needed to change – his mother was abruptly diagnosed with stage 4 cancer.  This compelled Savan to ask “where were all the signs” and “isn't there a better way,” which led to him returning to his Bioengineering roots and founding BioTrillion.

More Speakers

Subscribe for MWC 2020 Updates